生长抑素受体介导的放射性核素治疗  

Peptide Receptor Radionuclide Therapy with Somatostatin Receptor Analogues

作　　者：马温惠[1] 杨卫东[1] 李桂玉[1] 汪静[1] 

机构地区：[1]第四军医大学西京医院核医学科,陕西西安710032

出　　处：《现代生物医学进展》2012年第25期4956-4960,共5页Progress in Modern Biomedicine

基　　金：国家自然科学基金资助项目(30970846);国家重点基础研究发展计划(2011CB707704)

摘　　要：生长抑素受体介导的放射性核素治疗(peptide receptor radionuclide therapy,PRRT)是用于不能手术治疗或有远处转移的胃、肠和胰腺等神经内分泌肿瘤病人的一种新型治疗方法,本文旨在综述近年来不同核素标记生长抑素类似物的临床评价及相关研究。The somatostatin receptor is strongly over-expressed in most neuroendocrine tumours（NETs）,resulting in high tumour-to-background ratios.Peptide receptor radionuclide therapy（PRRT）with radiolabelled somatostatin analogues is an emerging and convincing treatment modality for patients with unresectable,somatostatin-receptor-positive NETs.Using radiolabelled somatostatin analogues for imaging became the gold standard for staging of NETs.This article reviews the effectiveness and safety of the different radiolabelled somatostatin analogues used.Furthermore,clinical issues-including indication,timing and side-effect of therapy-are discussed.Finally,important directions for future research are mentioned to illustrate new strategies for increasing therapy efficacy.

关 键 词：神经内分泌肿瘤 生长抑素受体 内放射治疗 放射性核素治疗 

分 类 号：R736[医药卫生—肿瘤] R817[医药卫生—临床医学]